Keywords
children, juvenile arthritis with systemic onset, tocilizumab
Abstract
The article presents the results of evaluating the effectiveness of a genetically engineered biological drug (tocilizumab) in children with juvenile arthritis with a systemic onset. Analysis of the results of the study showed that the use of a genetically engineered biological drug (tocilizumab) in the treatment of patients with juvenile arthritis with systemic onset contributes to a decrease in disease activity, regression of systemic signs and normalization of laboratory parameters in a significantly short time and improves the prognosis of the disease in these children.